ProHealth health Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help
Facebook Google Plus
Fibromyalgia  Chronic Fatigue Syndrome & M.E.  Lyme Disease  Natural Wellness  Supplement News  Forums  Our Story
Store     Brands   |   A-Z Index   |   Best Sellers   |   New Products   |   Deals & Specials   |   Under $10   |   SmartSavings Club

Trending News

On-and-off fasting helps fight obesity, study finds

Can Pomegranates Slow Aging?

Calorie restriction promotes longevity through effects on mitochondrial network

Discover Why Ashwagandha Can Be Used for Stress and Anxiety

Lower magnesium levels linked with increased mortality risk during up to 40 years of follow-up

A spoonful of oil: Fats and oils help to unlock full nutritional benefits of veggies, study suggests

Higher resveratrol dose linked to lower glucose levels in type 2 diabetics

How Can You Benefit From Vitamin B12?

Drug can dramatically reduce weight of people with obesity

What Is Bitter Orange?

 
Print Page
Email Article

A New Drug for Fibromyalgia (FM): Pregabalin is Shown to Improve Pain in FM Patients

  [ 1161 votes ]   [ Discuss This Article ]
www.ProHealth.com • November 8, 2002


Pfizer Inc.'s pregabalin was shown to provide improvement of pain in patients with fibromyalgia, a chronic and debilitating pain syndrome, according to data presented on October 26, 2002 at the annual meeting of the American College of Rheumatology. Pregabalin also was shown to improve sleep and fatigue levels, the data demonstrate.

Fibromyalgia syndrome (FMS) is a chronic disorder characterized by widespread musculoskeletal pain that is frequently associated with fatigue and sleep disturbances. It is estimated to affect two percent of the population, or 5.6 million Americans, and occurs most frequently in women.

The double-blind, placebo-controlled monotherapy study involved 529 patients diagnosed with FMS. Patients were randomized to receive placebo or pregabalin (150 mg, 300 mg or 450 mg per day) for eight weeks. The study evaluated the efficacy and safety of pregabalin for the treatment of pain and associated symptoms such as sleep and fatigue. Patients were required to characterize and record their pain on a daily basis in detailed diaries.

Pregabalin-treated patients (450 mg/day) showed statistically significant improvements in pain compared to those who received placebo. Further, 29 percent of pregabalin-treated patients reported at least a 50 percent reduction in pain, compared with a reduction of 13 percent for patients who received placebo, a difference that was statistically significant. In addition, pregabalin significantly improved sleep quality and fatigue.

"To demonstrate improvements in the core symptoms of FMS—pain, sleep and fatigue—represents an important advance, particularly as there are no approved treatments for this condition," said Dr. Leslie Crofford, lead investigator and associate professor of internal medicine, Division of Rheumatology, at the University of Michigan in Ann Arbor.

"FMS is highly debilitating for patients and difficult to treat, and we are in need of new treatment options that are both effective and well tolerated," Dr. Crofford said. "These data are highly encouraging because pregabalin was shown to provide significant relief from the most troublesome symptoms for patients."

The most common dose-related side effects reported by patients were dizziness and drowsiness. Most adverse events were mild to moderate in intensity, and many resolved during the study. Seventy-eight percent of all patients completed the study.

Developed by Pfizer, pregabalin has been studied in an extensive clinical program involving over 8,000 patients worldwide. The company has completed pivotal studies to support the filing of a New Drug Application for pregabalin for the treatment of neuropathic pain and generalized anxiety disorder and as an add-on therapy for epilepsy.

Pfizer Neuroscience is committed to pioneering innovative therapies for neurological and psychiatric disorders. Pfizer's experience in the areas of depression, anxiety, schizophrenia, Alzheimer's disease and epilepsy has helped bring leading medicines to market for the treatment of these disorders.



Post a Comment

Featured Products From the ProHealth Store
FibroSleep™ Optimized Curcumin Longvida® Energy NADH™ 12.5mg


Article Comments



Be the first to comment on this article!

Post a Comment


 
Optimized Curcumin Longvida with Omega-3

Featured Products

Ultra EPA  - Fish Oil Ultra EPA - Fish Oil
Ultra concentrated source of essential fish oils
FibroSleep™ FibroSleep™
The All-in-One Natural Sleep Aid
Mitochondria Ignite™ with NT Factor® Mitochondria Ignite™ with NT Factor®
Reduce Fatigue up to 45%
Vitamin D3 Extreme™ Vitamin D3 Extreme™
50,000 IU Vitamin D3 - Prescription Strength
Optimized Curcumin Longvida® Optimized Curcumin Longvida®
Supports Cognition, Memory & Overall Health

Natural Remedies

D-ficient? Health Risks You Need to Know About D-ficient? Health Risks You Need to Know About
Priming Your Immune System for Cold & Flu Season Priming Your Immune System for Cold & Flu Season
Stop Bacteria With Nature's Antibiotics Stop Bacteria With Nature's Antibiotics
The Fast-Acting Solution for Healthy Digestive Function The Fast-Acting Solution for Healthy Digestive Function
Why Berries Offer a Rainbow of Health Benefits Why Berries Offer a Rainbow of Health Benefits

CONTACT US
ProHealth, Inc.
555 Maple Ave
Carpinteria, CA 93013
(800) 366-6056  |  Email

· Become a Wholesaler
· Vendor Inquiries
· Affiliate Program
SHOP WITH CONFIDENCE
Credit Card Processing
SUBSCRIBE TO OUR NEWSLETTERS
Get the latest news about Fibromyalgia, M.E/Chronic Fatigue Syndrome, Lyme Disease and Natural Wellness

CONNECT WITH US ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus

© 2017 ProHealth, Inc. All rights reserved. Pain Tracker App  |  Store  |  Customer Service  |  Guarantee  |  Privacy  |  Contact Us  |  Library  |  RSS  |  Site Map